分類: 產學研發徵求夥伴

Latest news-English

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR807: A CXCR4-Targeted Antagonist” (2022/7/26)

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR807: A CXCR4-Targeted Antagonist” Date: 2022.7.26   1. Title: NHRI technology, “DBPR807: A CXCR4-Targeted Antagonist” (abbreviated as “The …

閱讀更多 →
技術轉移招商en文章

Technology Available for Industry-Academia Collaboration or Technology Licensing. “A Potential COVID-19 Therapeutic Compound”(2020/4/16)

Description The licensing technology is about a proprietary Madin-Darby canine kidney cell line (NHRI sMDCK) capable of growing in suspension culture without serum. Further disclosed …

閱讀更多 →
技術轉移招商en文章

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR807: a CXCR4-Targeted Antagonist”(2019/07/24)

Title: NHRI technology, “DBPR807: a CXCR4-Targeted Antagonist” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing. Description: DBPR807 is a potent antagonist targeting …

閱讀更多 →
技術轉移招商en文章

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR215: A Stem Cell Mobilizer for Cell Based Therapy”(2019/07/24)

Title: NHRI technology, “DBPR215: A Stem Cell Mobilizer for Cell Based Therapy” (abbreviated as “The Technology”) available for industry-academia collaboration technology licensing. Description: DBPR807 is …

閱讀更多 →
產學研發徵求夥伴en文章

Technology Available for Industry-Academia Collaboration or Technology Licensing. “DBPR114: a multi-targeted kinase inhibitor for solid tumors”(2018/12/13)

Title: NHRI technology, “DBPR114: a multi-targeted kinase inhibitor for solid tumors” (abbreviated as “The Technology”) available for industry-academia collaboration or technology licensing. Description: DBPR114 is …

閱讀更多 →